https://www.marketscreener.com/quote/stock/ANAPTYSBIO-INC-33634949/news/AnaptysBio-Reports-Imsidolimab-ACORN-Phase-2-Clinical-Trial-Data-in-Moderate-to-Severe-Acne-39759360/?utm_source=telegram&utm_medium=social&utm_campaign=share